Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Assessment of TP53 lesions for p53 system functionality and drug resistance in multiple myeloma using an isogenic cell line model.

Scientific reports - 2 Dec 2019

Munawar Umair, Roth Markus, Barrio Santiago, Wajant Harald, Siegmund Daniela, Bargou Ralf C, Kortüm K Martin, Stühmer Thorsten

Abstract excerpt

Recent advances in molecular diagnostics have shown that lesions affecting both copies of the gene for tumor suppressor protein 53 (TP53) count among the most powerful predictors for high-risk disease in multiple myeloma (MM). However, the functional relevance and potential therapeutic implications of single hits to TP53 remain less well understood. Here, we have for the first time approximated the different...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Alkylating
Share to CRISPR-Cas Systems

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Gene Editing

Share to Melphalan

Share to Multiple Myeloma

Share to Point Mutation

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 31792264
DOI: 10.1038/s41598-019-54407-4
PMCID: PMC6889167

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Assessment of TP53 lesions for p53 system functionality and drug resistance in multiple myeloma using an isogenic cell line model.PMID 31792264Read ↗

Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma.Semantic proximity Read ↗

Deregulation and Targeting of TP53 Pathway in Multiple MyelomaSemantic proximity Read ↗

p53 haploinsufficiency and functional abnormalities in multiple myeloma.Semantic proximity Read ↗

The frequency and clinical outcome of mono-hit and multi-hit TP53 aberrations in newly diagnosed multiple myeloma.Semantic proximity Read ↗

Multi-omic and functional screening reveal targetable vulnerabilities in<i>TP53</i>mutated multiple myelomaSemantic proximity Read ↗

Molecular spectrum of TP53 mutations in plasma cell dyscrasias by next generation sequencing: an Italian cohort study and overview of the literature.Semantic proximity Read ↗

Novel Scheme for Defining the Clinical Implications of TP53 Mutations in Myeloid NeoplasiaSemantic proximity Read ↗

Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myelomaSemantic proximity Read ↗

Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes.Semantic proximity Read ↗

An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myelomaSemantic proximity Read ↗

Novel scheme for defining the clinical implications of TP53 mutations in myeloid neoplasia.Semantic proximity Read ↗

Prevalence and timing of TP53 mutations in del(17p) myeloma and effect on survivalSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.